InvestSMART

Australian Clinical Labs Limited (ASX: ACL) - Announcements

- Current share price for ACL : $2.880

ASX company news and announcements for Australian Clinical Labs Limited (ACL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Australian Clinical Labs Limited (ACL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Australian Clinical Labs Limited (ACL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Australian Clinical Labs Limited (ACL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$537 Appendix 4C - quarterly 20 Oct 2011 8:27AM $0.285 $2.880 risen by 910.53%
$537 Alchemia`s Cancer Treatment Shows Early Promise In Trial 28 Sep 2011 8:26AM $0.350 $2.880 risen by 722.86%
$537 Initiation Of Phase 2 Trial In Small Cell Lung Cancer 9 Sep 2011 8:25AM $0.435 $2.880 risen by 562.07%
$537 Preliminary Final Report 26 Aug 2011 3:48PM $0.320 $2.880 risen by 800%
$537 Market Update On Fondaparinux 9 Aug 2011 9:59AM $0.330 $2.880 risen by 772.73%
$537 Patent Update 27 Jul 2011 8:27AM $0.670 $2.880 risen by 329.85%
$537 Appendix 4C - quarterly 25 Jul 2011 8:25AM n/a $2.880 n/a
$537 USFDA Approval of Fondaparinux Sodium Injection 13 Jul 2011 3:13PM $0.800 $2.880 risen by 260%
$537 Trading Halt 12 Jul 2011 10:40AM $0.615 $2.880 risen by 368.29%
$537 Update On Pending FDA Approval Of Fondaparinux and App. 4C 11 Apr 2011 5:53PM n/a $2.880 n/a
$537 Appendix 4D 22 Feb 2011 11:45AM $0.350 $2.880 risen by 722.86%
$537 Appendix 4C - quarterly 28 Jan 2011 12:45PM $0.660 $2.880 risen by 336.36%
$537 Appendix 4C - quarterly 22 Oct 2010 2:07PM $0.525 $2.880 risen by 448.57%
$537 Preliminary Final Report 25 Aug 2010 4:12PM $0.490 $2.880 risen by 487.76%
$537 Appendix 4C - quarterly 29 Jul 2010 8:30AM $0.540 $2.880 risen by 433.33%
$537 Alchemia and Dr Reddys expand marketing collaboration 15 Jul 2010 8:39AM $0.390 $2.880 risen by 638.46%
$537 Alchemia Phase III trial adopted by the UK NCRN 12 Jul 2010 9:59AM $0.390 $2.880 risen by 638.46%
$537 Competitor files DMF for Fondaparinux Sodium 7 Jul 2010 10:37AM $0.360 $2.880 risen by 700%
$537 Alchemia Receives $1m Grant for Novel Pain Killer Project 4 May 2010 10:32AM $0.535 $2.880 risen by 438.32%
$537 Appendix 4C - quaterly 19 Apr 2010 9:21AM $0.585 $2.880 risen by 392.31%
$537 Oral Fondaparinux Collaboration 19 Mar 2010 8:58AM $0.670 $2.880 risen by 329.85%
$537 Chinese Patent Granted 8 Mar 2010 9:20AM $0.640 $2.880 risen by 350%
$537 Half yearly Rport and Accounts 24 Feb 2010 3:03PM $0.610 $2.880 risen by 372.13%
$537 Quaterly Cashflow Report 28 Jan 2010 12:31PM $0.700 $2.880 risen by 311.43%
$537 Response to ASX Price Query 18 Jan 2010 9:18AM $0.790 $2.880 risen by 264.56%

901 - 925 of 1019 results

Page 37 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.